Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Nicholas Squittieri"'
Autor:
Michael Migden, MD, Carmen Loquai, MD, PhD, Caroline Robert, MD, PhD, Jean-François Baurain, MD, PhD, Nicholas Squittieri, MD, Ramon Arntz, Dr, Jörg Dierlamm, BSc, Brigitte Dréno, MD, PhD
Publikováno v:
JAAD International, Vol 10, Iss , Pp 31-33 (2023)
Externí odkaz:
https://doaj.org/article/cef753bd4f664a878bb31435c541a8c2
Publikováno v:
JAAD International, Vol 6, Iss , Pp 13-19 (2022)
Background: The effects of halobetasol propionate (HBP) lotion 0.05% on the hypothalamic-pituitary-adrenal (HPA) axis have not been previously evaluated in adolescents. Objective: To examine the effect of HBP on HPA axis suppression in patients aged
Externí odkaz:
https://doaj.org/article/9b2fd133847845d3a895f520e3ec634f
Autor:
Ralf Gutzmer, Caroline Robert, Carmen Loquai, Dirk Schadendorf, Nicholas Squittieri, Ramon Arntz, Serena Martelli, Reinhard Dummer
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-9 (2021)
Abstract Background The BOLT study for sonidegib, a Hedgehog pathway inhibitor (HHI) approved for patients with locally advanced basal cell carcinoma (laBCC) not amenable to curative surgery or radiotherapy, used modified Response Evaluation Criteria
Externí odkaz:
https://doaj.org/article/9318906b3570461fb547c379286e05d0
Autor:
Adelaide Hebert, Lawrence Eichenfield, Diane Thiboutot, Linda Stein Gold, Snejina Vassileva, Yanita Mihaylova, Martina Cartwright, Luigi Moro, Enrico Fragasso, Jenny Han, Nicholas Squittieri, Alessandro Mazzetti
Publikováno v:
Journal of Drugs in Dermatology. 22:174-181
Publikováno v:
Endocrine Practice. 28:414-419
Subcutaneous injections of octreotide acetate require chronic administration by health care providers (HCPs). We aimed to validate the safe and effective use of the octreotide acetate pen injector, its labeling, and instructions for use (IFU) by pati
Autor:
Reinhard Dummer, Aaron S. Farberg, Michael R. Migden, Alexander Guminski, Karl D. Lewis, Nicholas Squittieri
Publikováno v:
Dermatology and Therapy
Introduction Sonidegib is a Hedgehog pathway inhibitor approved to treat locally advanced basal cell carcinoma and, depending on regulatory approval, metastatic basal cell carcinoma. Results from the BOLT study demonstrated robust efficacy and contin
Autor:
R. Gutzmer, Karl D. Lewis, Serena Martelli, Brigitte Dréno, Carmen Loquai, Meenal Kheterpal, Ramon Arntz, Nicholas Squittieri, Caroline Robert, Alexander Guminski
Publikováno v:
Dermatology and Therapy
Introduction Sonidegib is approved to treat locally advanced basal cell carcinoma (laBCC) in the USA, EU, Switzerland, and Australia and metastatic basal cell carcinoma (mBCC) in Switzerland and Australia in patients not amenable to surgery or radiot
Autor:
Michael, Migden, Carmen, Loquai, Caroline, Robert, Jean-François, Baurain, Nicholas, Squittieri, Ramon, Arntz, Jörg, Dierlamm, Brigitte, Dréno
Publikováno v:
Journal of The American Academy of Dermatology
Journal of The American Academy of Dermatology, 2022, Online ahead of print. ⟨10.1016/j.jdin.2022.08.027⟩
Journal of The American Academy of Dermatology, 2022, Online ahead of print. ⟨10.1016/j.jdin.2022.08.027⟩
International audience
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dcbdb319bb0f696c38cc45f389915fd9
https://www.hal.inserm.fr/inserm-03818996/document
https://www.hal.inserm.fr/inserm-03818996/document
Autor:
Alexander Guminski, Peter Foley, Jean-Jacques Grob, Caroline Robert, Ralf Gutzmer, Nicholas Squittieri, Felix Kiecker
Publikováno v:
SKIN The Journal of Cutaneous Medicine. 7:s181
Autor:
Michael Migden, Alexander Guminski, Ralf Gutzmer, Carmen Loquai, Nicholas Squittieri, Peter Foley
Publikováno v:
SKIN The Journal of Cutaneous Medicine. 7:s180